Evidence map›Paper›PMID 24754003›Full record

ReviewAdvanced pharmaceutical bulletin2014

The prelude on novel receptor and ligand targets involved in the treatment of diabetes mellitus.

Venu Gopal Jonnalagadda, Allam Venkata Sita Ram Raju, Srinivas Pittala, Afsar Shaik, Nilakash Annaji Selkar

Open access · greenAbstract readReview
In one paragraph

Review in Advanced pharmaceutical bulletin, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 2 countries.

Venu Gopal JonnalagaddaShree Dhootapapeshwar Ayurvedic Research Foundation (SDARF), Panvel, Navi Mumbai-410206, Maharastra, India.
Allam Venkata Sita Ram RajuNational Institute of Pharmaceutical Education and Research, Bala Nagar, Hyderabad, Andhra Pradhesh-500037, India.
Srinivas PittalaCSIR-Institute of Genomics and Integrative Biology, Near Jubilee Hall, Mall Road, Delhi-110 007, India.
Afsar ShaikGokula Krishna college of Pharmacy, Sullurpet - 524121, Nellore dist, A.P, India.
Nilakash Annaji SelkarNational Institute for Research in Reproductive Health, Parel, Mumbai-400012, Maharastra, India.
Ayurvedic Institute · USGokula Krishna College of Pharmacy · INInstitute of Genomics and Integrative Biology · INNational Institute for Research in Reproductive Health · INNational Institute of Pharmaceutical Education and Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic disorders are a group of disorders, due to the disruption of the normal metabolic process at a cellular level. Diabetes Mellitus and Tyrosinaemia are the majorly reported metabolic disorders. Among them, Diabetes Mellitus is a one of the leading metabolic syndrome, affecting 5 to 7 % of the population worldwide and mainly characterised by elevated levels of glucose and is associated with two types of physiological event disturbances such as impaired insulin secretion and insulin resistance. Up to now, various treatment strategies are like insulin, alphaglucosidase inhibitors, biguanides, incretins were being followed. Concurrently, various novel therapeutic strategies are required to advance the therapy of Diabetes mellitus. For the last few decades, there has been an extensive research in understanding the metabolic pathways involved in Diabetes Mellitus at the cellular level and having the profound knowledge on cell-growth, cell-cycle, and apoptosis at a molecular level provides new targets for the treatment of Diabetes Mellitus. Receptor signalling has been involved in these mechanisms, to translate the information coming from outside. To understand the various receptors involved in these pathways, we must have a sound knowledge on receptors and ligands involved in it. This review mainly summarises the receptors and ligands which are involved the Diabetes Mellitus. Finally, researchers have to develop the alternative chemical moieties that retain their affinity to receptors and efficacy. Diabetes Mellitus being a metabolic disorder due to the glucose surfeit, demands the need for regular exercise along with dietary changes.

Indexed as

Diabetes MellitusLigandsReceptorssignalling

Identifiers

PMID24754003
PMCPMC3992955
OpenAlexW2154788673

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.